Lhyfe S.A.S [LHYFE] vs Arkema S.A [AKE] Detailed Stock Comparison
Lhyfe S.A.S
Euronext
Loading...
Arkema S.A
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Lhyfe S.A.S wins in 5 metrics, Arkema S.A wins in 12 metrics, with 0 ties. Arkema S.A appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Lhyfe S.A.S | Arkema S.A | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -5.26 | 24.40 | Lhyfe S.A.S |
| Price-to-Book Ratio | 2.14 | 0.76 | Arkema S.A |
| Debt-to-Equity Ratio | 111.86 | 50.89 | Arkema S.A |
| PEG Ratio | 0.41 | 6.31 | Lhyfe S.A.S |
| EV/EBITDA | -5.82 | 6.14 | Lhyfe S.A.S |
| Profit Margin (TTM) | 82.53% | 2.39% | Lhyfe S.A.S |
| Operating Margin (TTM) | -458.65% | 7.56% | Arkema S.A |
| EBITDA Margin (TTM) | N/A | 7.56% | N/A |
| Return on Equity | -33.53% | 2.93% | Arkema S.A |
| Return on Assets (TTM) | -8.49% | 2.31% | Arkema S.A |
| Free Cash Flow (TTM) | $-62.04M | $360.00M | Arkema S.A |
| 1-Year Return | -19.55% | -21.13% | Lhyfe S.A.S |
| Price-to-Sales Ratio (TTM) | 30.19 | 0.49 | Arkema S.A |
| Enterprise Value | $161.56M | $7.21B | Arkema S.A |
| EV/Revenue Ratio | 31.69 | 0.76 | Arkema S.A |
| Gross Profit Margin (TTM) | N/A | 19.00% | N/A |
| Revenue per Share (TTM) | $0 | $125 | Arkema S.A |
| Earnings per Share (Diluted) | $-0.61 | $2.52 | Arkema S.A |
| Beta (Stock Volatility) | 1.35 | 1.02 | Arkema S.A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Lhyfe S.A.S vs Arkema S.A Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Lhyfe S.A.S | 0.00% | 0.63% | -8.29% | -0.62% | -9.83% | 7.72% |
| Arkema S.A | 1.38% | 7.50% | -1.81% | -4.95% | -21.87% | -12.92% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Lhyfe S.A.S | -19.55% | -60.52% | -62.85% | -62.85% | -62.85% | -62.85% |
| Arkema S.A | -21.13% | -31.63% | -32.84% | -11.94% | 10.14% | 10.14% |
Performance & Financial Health Analysis: Lhyfe S.A.S vs Arkema S.A
| Metric | LHYFE | AKE |
|---|---|---|
| Market Information | ||
| Market Cap | €153.95M | €4.64B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 9,228 | 211,586 |
| 90 Day Avg. Volume | 14,898 | 236,290 |
| Last Close | €3.21 | €62.35 |
| 52 Week Range | €2.28 - €4.28 | €56.90 - €88.40 |
| % from 52W High | -25.00% | -29.47% |
| All-Time High | €9.50 (Oct 24, 2022) | €134.95 (Jan 17, 2022) |
| % from All-Time High | -66.21% | -53.80% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 2.69% | -0.06% |
| Quarterly Earnings Growth | N/A | -0.68% |
| Financial Health | ||
| Profit Margin (TTM) | 0.83% | 0.02% |
| Operating Margin (TTM) | -4.59% | 0.08% |
| Return on Equity (TTM) | -0.34% | 0.03% |
| Debt to Equity (MRQ) | 111.86 | 50.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €1.50 | €81.33 |
| Cash per Share (MRQ) | €1.51 | €17.38 |
| Operating Cash Flow (TTM) | €-26,971,000 | €1.02B |
| Levered Free Cash Flow (TTM) | €-45,611,124 | €342.75M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Lhyfe S.A.S vs Arkema S.A
| Metric | LHYFE | AKE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -5.26 | 24.40 |
| Forward P/E | -10.79 | 6.31 |
| PEG Ratio | 0.41 | 6.31 |
| Price to Sales (TTM) | 30.19 | 0.49 |
| Price to Book (MRQ) | 2.14 | 0.76 |
| Market Capitalization | ||
| Market Capitalization | €153.95M | €4.64B |
| Enterprise Value | €161.56M | €7.21B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 31.69 | 0.76 |
| Enterprise to EBITDA | -5.82 | 6.14 |
| Risk & Other Metrics | ||
| Beta | 1.35 | 1.02 |
| Book Value per Share (MRQ) | €1.50 | €81.33 |
Financial Statements Comparison: Lhyfe S.A.S vs Arkema S.A
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | LHYFE | AKE |
|---|---|---|
| Revenue/Sales | N/A | €2.38B |
| Cost of Goods Sold | N/A | €1.94B |
| Gross Profit | N/A | €441.00M |
| Research & Development | N/A | €71.00M |
| Operating Income (EBIT) | N/A | €124.00M |
| EBITDA | N/A | €329.00M |
| Pre-Tax Income | N/A | €78.00M |
| Income Tax | N/A | €28.00M |
| Net Income (Profit) | N/A | €50.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | LHYFE | AKE |
|---|---|---|
| Cash & Equivalents | €72.12M | €1.12B |
| Total Current Assets | €95.84M | €4.42B |
| Total Current Liabilities | €51.42M | €1.82B |
| Long-Term Debt | €71.04M | €3.67B |
| Total Shareholders Equity | €71.68M | €7.59B |
| Retained Earnings | €-29.09M | €4.67B |
| Property, Plant & Equipment | €40.26M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | LHYFE | AKE |
|---|---|---|
| Operating Cash Flow | N/A | €50.00M |
| Capital Expenditures | N/A | €-96.00M |
| Free Cash Flow | N/A | €-168.00M |
| Debt Repayment | N/A | €-28.00M |
| Common Stock Repurchase | N/A | €-17.00M |
Short Interest & Institutional Ownership Analysis
| Metric | LHYFE | AKE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 9,228 | 211,586 |
| Average Daily Volume (90 Day) | 14,898 | 236,290 |
| Shares Outstanding | 47.87M | 75.80M |
| Float Shares | 15.95M | 56.70M |
| % Held by Insiders | 0.61% | 0.10% |
| % Held by Institutions | 0.09% | 0.58% |
Dividend Analysis & Yield Comparison: Lhyfe S.A.S vs Arkema S.A
| Metric | LHYFE | AKE |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |